Brain metastases are the most common type of brain tumors, and it is estimated that about 1/3 of cancer patients will
develop brain metastases.
In the case of breast cancer driven by overexpression of the HER2 gene, up to 50 percent of patients treated with targeted therapies eventually
develop brain metastases, which are inevitably fatal.
Approximately 30 percent of patients with cancer
develop brain metastases, and the incidence of these lesions is rising.
«If you look at a set of lung cancer patients, like we did in the paper, who
develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.
Approximately eight to ten percent of cancer patients will
develop brain metastases, and treatment options are limited.
Only a minority of fibrolamellar patients will
develop brain metastases, Simon expects.
Not exact matches
In their search for novel, tumor - specific therapies that could target multiple
brain metastases without damaging adjacent tissues, the research team first
developed a mouse model that more closely mimics what is seen in patients.